Acute coronary occlusion during valve-in-valve TAVI is a life-threatening complications. A transcatheter leaflet splitting dedicate device is available to prevent the acute coronary occlusion. Read more in #EHJ. doi.org/10.1093/eurhea… #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

Hot off the press! Our latest study in @Circulation reports 1-year outcomes for transseptal Mitral Valve-in-Valve, featuring the largest dataset to date! With the recent approval for intermediate risk, discover the impressive results of transseptal mitral VIV in patients with

In the bRIGHT study, tricuspid #TEER with #TriClip is safe and effective through 1-yr for significant TR in a real-world population bit.ly/4bEVbEE #JACC #vhdTR Univ.-Prof. Dr. Ralph Stephan von Bardeleben Karl-Philipp Rommel

In a cohort study, glycated hemoglobin levels markedly underestimated glucose levels in patients with G6PD deficiency, which indicates that this marker may be unreliable for diagnosis and management of diabetes in this population. Full correspondence: nej.md/3WRNTZq

📢 A NEW #ISHLT Guideline Document for the evaluation and care of #HeartTransplant candidates is now available. 📖🫀 This document provides recommendations based on contemporary scientific evidence & patient management flow diagrams. Check out the top ten takeaways ⏬ and read

Asaf Vivante, M.D., Ph.D., discusses the diagnosis and management of CKD of genetic origin in adults, focusing on single-gene variants that cause or confer a substantial risk of progressive CKD. Read the full review: nej.md/3SMFpAv

Namibia. Wow. Incredible geology and landscapes, with amazing wildlife. Crowd free. Very interesting history. Great weather during August. Wonderful option for a family vacation. #holiday

AISAP receives FDA approval for cardiac ultrasound software platform. The cloud-based platform combines AI diagnostics and detailed measurements for rapid and accurate diagnosis of structural heart disease. calcalistech.com/ctechnews/arti…

Super excited to share: AISAP AI-powered POCUS Diagnostic Software Receives FDA Clearance. Big news for #POCUS enthusiastics. read more here: aisap.ai. This will change medicine and will empower doctors anywhere. NephroPOCUS #CardioTwitter Sheba Medical Center

This is big. finance.yahoo.com/news/aisap-car…

AISAP announced the FDA granted 510(k) clearance for its first-in-class, AI-powered point-of-care ultrasound software platform for the measurement of several cardiac pathologies #Cardiotwitter U.S. FDA #AIinMedicine Read more👇 healio.com/news/cardiolog…

מנסה לצייץ בעברית. חברת aisap.ai משיבא קיבלה אישור FDA למוצר שישנה את פני הרפואה. מדובר בתוכנה מבוססת AI שמעצימה רופאים שאינם קרדיולוגים ומאפשרת להם לאבחן מחלות לב בחדרי מיון מרפאות ומחלקות פנימיות. חבל שהאלגוריתם של X לא מבין שזה חייב להיות וירלי עידו וולף

FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform diagnosticimaging.com/view/fda-clear… ACR RFS ACR YPS American College of Radiology ARRS RSNA AIUM Ultrasound Society of Point-of-Care Ultrasound (SPOCUS) Duke Radiology Northwestern Radiology Tulane Radiology Michigan Radiology UTSW Radiology #radiology #RadRes

FDA clears AI-powered POCUS platform for structural heart disease, heart failure #cardiology #cardiotwitter #AI #deeplearning ow.ly/hWkm50T57Bb

AISAP’s CARDIO AI-powered Point-of-Care Ultrasound Diagnostic Assessment Software Receives FDA Clearance - businesswire.com/news/home/2024…

RESHAPE-HF2 shows no impact on mortality but significant reduction in HFH and improvement in KCCQ. All call for a larger trial to confirm MTEER for lower risk and lower MR severity. #ESC2024

Percutaneous Transcatheter Edge-To-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Meta-Analysis of 3 Randomized Controlled Trials | Journal of the American College of Cardiology jacc.org/doi/10.1016/j.… JACC Journals

💡 Simple may be best for #TTVR in patients with severe #TR. Trillium is a streamlined solution with a shorter implantation time and no echo guidance or general anesthesia needed. 🏥 #NYValves2024 📊 👉 tctmd.com/slide/heteroto… Philipp Lurz #InnovationWithPurpose Guido Ascione

In patients w/ an ACS on maximal tolerated statin randomized to the PCSK9 inhibitor alirocumab vs. placebo, baseline triglyceride levels predicted MACE, even after adjustment for covariates associated with triglyceride levels and risk of MACE including diabetes and HDL-C.

Excited to share the opening video of my 7-minute talk on transforming bedside diagnosis with AI and handheld ultrasound. Real-time, accurate heart disease diagnosis is now possible with minimal training. FDA approved. Read more: aisap.ai #POCUS #CardioTwitter